drugset
drugset / Trial / NCT07059221

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

NCT07059221 ↗

Phase 1/2 Recruiting 210 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839（sc） for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Timeline

Start
2025-07-11
Primary completion
2027-03
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody — Intravenous
Subject Carboplatin Small molecule — Intravenous
Subject Cetuximab Monoclonal antibody — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject SHR-9839(sc) Unknown — Subcutaneous
Subject SHR-A2102 Other / unclassified — Intravenous

Indications

head and neck squamous cell carcinoma